Tarlatamab-associated CRS was manageable with supportive care, including acetaminophen or paracetamol, intravenous fluids, supplemental oxygen (where required), and in some cases, tocilizumab (anti–IL-6 monoclonal antibody); however, only 8/107 patients (7.5%) required the use of tocilizumab for CRS in this trial at the time of data cutoff. This evidence concerns the gene IL6 and congenital rubella syndrome.